New drug combo aims to control bladder cancer when standard therapy fails

NCT ID NCT06503614

Recruiting now Disease control Sponsor: John Sfakianos Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two drugs, durvalumab and monalizumab, given together to people with a type of bladder cancer that has not gotten better with standard treatment. The goal is to see if the combination can make the cancer disappear or stop it from growing. About 60 adults will take part, receiving the drugs by IV once a month for up to 13 cycles.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCG-UNRESPONSIVE OR BCG-EXPOSED CARCINOMA IN SITU NON-MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder carcinoma in situ bladder papillary urothelial carcinoma non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER CANCER NON-MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08903, United States
Weill Cornell Medical Center
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.